The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies
by
Christine Rasetti-Escargueil 1,*,†
,
Arnaud Avril 2,3,*,†,‡,
Sebastian Miethe 4,
Christelle Mazuet 1,
Yagmur Derman 5,
Katja Selby 5,
Philippe Thullier 2,
Thibaut Pelat 2,6,§,
Remi Urbain 7,8,
Alexandre Fontayne 7,
Hannu Korkeala 5,
Dorothea Sesardic 9,
Michael Hust 4 and
Michel R. Popoff 1
Christine Rasetti-Escargueil 1,*,†,
Arnaud Avril 2,3,*,†,‡,
Sebastian Miethe 4,
Christelle Mazuet 1,
Yagmur Derman 5,
Katja Selby 5,
Philippe Thullier 2,
Thibaut Pelat 2,6,§,
Remi Urbain 7,8,
Alexandre Fontayne 7,
Hannu Korkeala 5,
Dorothea Sesardic 9,
Michael Hust 4 and
Michel R. Popoff 1
1
Institut Pasteur, Unité des Bactéries Anaérobies et Toxines, 25 Avenue du Docteur Roux, 75015 Paris, France
2
Institut de Recherche Biomédicale des Armées (IRBA-CRSSA), Département de Microbiologie, Unité de Biotechnologie des Anticorps et Des Toxins, Cedex 38702 La Tronche, France
3
Institut de Recherche Biomédicale des Armées (IRBA), Département des Maladies Infectieuses, Unité Biothérapies anti-Infectieuses et Immunité, 1 Place du Général Valérie André, BP73, 91220 Brétigny-sur-Orge, France
4
Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Spielmannstr. 7, 38106 Braunschweig, Germany and YUMAB GmbH, Rebenring 33, Braunschweig 38106, Germany
5
Department of Food Hygiene and Environmental Health, University of Helsinki, P.O. Box 66, FI-00014 Helsinki, Finland
6
BIOTEM, Parc d’activité Bièvre Dauphine 885, Rue Alphonse Gourju, 38140 Apprieu, France
7
LFB Biotechnologies, Therapeutic Innovation Department, 59, Rue de Trévise, BP 2006-59011 Lille Cedex, France
8
Ecdysis Pharma, Bioincubateur Eurasanté, 70 Rue du Dr Yersin, 59120 Loos, France
9
National Institute for Biological Standards and Control (NIBSC), a Center of the Medicines and Healthcare Products Regulatory Agency, Division of Bacteriology, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
*
Authors to whom correspondence should be addressed.
†
First and second author contributed equally to the review.
‡
Present address for Arnaud Avril: Institut de Recherche Biomédicale des Armées (IRBA) Département des Maladies Infectieuses, Unité Biothérapies anti-Infectieuses et Immunité, 1 Place du Général Valérie André, BP73, 91220 Brétigny-sur-Orge, France.
§
Present address for Thibault Pelat: BIOTEM, Parc D’activité Bièvre Dauphine 885, Rue Alphonse Gourju 38140 Apprieu, France and for Rémi Urbain: Ecdysis Pharma, Bioincubateur Eurasanté, 70 Rue du Dr Yersin, 59120 Loos, France.
Academic Editors: Jianlong Lou and James D. Marks
Toxins 2017, 9(10), 309; https://doi.org/10.3390/toxins9100309
Received: 11 August 2017 / Revised: 15 September 2017 / Accepted: 16 September 2017 / Published: 2 October 2017
(This article belongs to the Special Issue Botulinum Neurotoxins Antibody and Vaccine)
The goal of the AntiBotABE Program was the development of recombinant antibodies that neutralize botulinum neurotoxins (BoNT) A, B and E. These serotypes are lethal and responsible for most human botulinum cases. To improve therapeutic efficacy, the heavy and light chains (HC and LC) of the three BoNT serotypes were targeted to achieve a synergistic effect (oligoclonal antibodies). For antibody isolation, macaques were immunized with the recombinant and non-toxic BoNT/A, B or E, HC or LC, followed by the generation of immune phage-display libraries. Antibodies were selected from these libraries against the holotoxin and further analyzed in in vitro and ex vivo assays. For each library, the best ex vivo neutralizing antibody fragments were germline-humanized and expressed as immunoglobulin G (IgGs). The IgGs were tested in vivo, in a standardized model of protection, and challenged with toxins obtained from collections of Clostridium strains. Protective antibody combinations against BoNT/A and BoNT/B were evidenced and for BoNT/E, the anti-LC antibody alone was found highly protective. The combination of these five antibodies as an oligoclonal antibody cocktail can be clinically and regulatorily developed while their high “humanness” predicts a high tolerance in humans.
View Full-Text
Keywords:
AntiBotABE; botulinum; toxin; phage-display; IgG; neutralization; botulism; biodefense; recombinant; oligoclonal antibodies
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Rasetti-Escargueil, C.; Avril, A.; Miethe, S.; Mazuet, C.; Derman, Y.; Selby, K.; Thullier, P.; Pelat, T.; Urbain, R.; Fontayne, A.; Korkeala, H.; Sesardic, D.; Hust, M.; Popoff, M.R. The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies. Toxins 2017, 9, 309.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
